Warnings and Precautions Insulin pens, needles, or syringes must never be shared between patients. Do NOT reuse needles. Monitor blood glucose in all patients treated with insulin. Modify insulin regimen cautiously and only under medical supervision.
|Published (Last):||2 April 2006|
|PDF File Size:||18.5 Mb|
|ePub File Size:||1.85 Mb|
|Price:||Free* [*Free Regsitration Required]|
For patients without insurance there is an offer too. Terms and Eligibility Restrictions Apply. Only people without prescription medication insurance can apply for this offer.
Void where prohibited by law. Offer valid for one fill per month. When using the Insulins Valyou Savings Card, prices are guaranteed for 12 consecutive monthly fills. The Insulins Valyou Savings Program applies to the cost of medication. If you have an Affordable Care Health Care Exchange plan, you may still be qualified to receive and use this savings card. Maximum savings apply. Upon registration, patients receive all program details. Sanofi US reserves the right to change the maximum cap amount, rescind, revoke or amend these programs without notice.
Reference: All registered trademarks cited are property of their respective owners. Lantus is a long-acting insulin analog indicated to improve glycemic control in adults and pediatric patients with type 1 diabetes mellitus and in adults with type 2 diabetes mellitus.
Lantus should be administered once a day at the same time every day. Limitations of Use: Lantus is not recommended for the treatment of diabetic ketoacidosis. Important Safety Information Contraindications Lantus is contraindicated during episodes of hypoglycemia and in patients hypersensitive to insulin glargine or one of its excipients.
Warnings and Precautions Insulin pens, needles, or syringes must never be shared between patients. Do NOT reuse needles. Monitor blood glucose in all patients treated with insulin. Modify insulin regimen only under medical supervision. Changes in insulin regimen including, strength, manufacturer, type, injection site or method of administration may result in the need for a change in insulin dose or an adjustment in concomitant oral antidiabetic treatment.
Repeated insulin injections into areas of lipodystrophy or localized cutaneous amyloidosis may result in hyperglycemia; sudden change in the injection site to unaffected area has been reported to result in hypoglycemia. Advise patients to rotate injection site to unaffected areas and closely monitor for hypoglycemia. Do not dilute or mix Lantus with any other insulin or solution. Do not administer Lantus via an insulin pump or intravenously because severe hypoglycemia can occur.
Hypoglycemia is the most common adverse reaction of insulin therapy, including Lantus, and may be life-threatening. Medication errors, such as accidental mix-ups between basal insulin products and other insulins, particularly rapid-acting insulins, have been reported. Patients should be instructed to always verify the insulin label before each injection.
Severe life-threatening, generalized allergy, including anaphylaxis, can occur. Discontinue Lantus, treat and monitor until symptoms resolve. A reduction in the Lantus dose may be required in patients with renal or hepatic impairment. As with all insulins, Lantus use can lead to life-threatening hypokalemia. Untreated hypokalemia may cause respiratory paralysis, ventricular arrhythmia, and death. Closely monitor potassium levels in patients at risk of hypokalemia and treat if indicated.
Fluid retention, which may lead to or exacerbate heart failure, can occur with concomitant use of thiazolidinediones TZDs with insulin. These patients should be observed for signs and symptoms of heart failure. If heart failure occurs, dosage reduction or discontinuation of TZD must be considered. Drug Interactions Certain drugs may affect glucose metabolism, requiring insulin dose adjustment and close monitoring of blood glucose.
The signs of hypoglycemia may be reduced in patients taking anti-adrenergic drugs e. Adverse Reactions Adverse reactions commonly associated with Lantus include hypoglycemia, allergic reactions, injection site reactions, lipodystrophy, pruritus, rash, edema and weight gain.
To help ensure an accurate dose each time, patients should follow all steps in the Instruction Leaflet accompanying the pen: otherwise they may not get the correct amount of insulin, which may affect their blood glucose.
Sales Professional Virtual Support is intended to be temporary until further notice. Please contact your Sales Professional directly or call Sanofi Medical Information Services at with your questions. Regarding sample requests for certain products, please visit our Sanofi Services Portal. Limitations of Use: Has not been studied in patients with a history of pancreatitis.
Do not inject into areas of lipodystrophy or localized cutaneous amyloidosis [see Warnings and Precautions 5. Only use if the solution is clear and colorless with no visible particles. Do not administer intravenously or via an insulin pump. The SoloStar prefilled pen is for single patient use only [see Warnings and Precautions 5.